- Home
- PETS vs NOTV Comparison
PETS vs NOTV Comparison
Compare PETS & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | NOTV |
|---|---|---|
| Founded | 1996 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 12.7M |
| IPO Year | 2003 | 1997 |
Fundamental Metrics
Financial Performance| Metric | PETS | NOTV |
|---|---|---|
| Price | $2.49 | $0.39 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.20 | $1.50 |
| AVG Volume (30 Days) | 122.5K | ★ 575.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 49.64 |
| EPS | N/A | ★ N/A |
| Revenue | $273,800,000.00 | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | $2.98 | $5.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $1.57 | $0.25 |
| 52 Week High | $4.32 | $3.35 |
Technical Indicators
Market Signals| Indicator | PETS | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 53.23 |
| Support Level | $2.44 | $0.26 |
| Resistance Level | $2.93 | $0.65 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 5.07 | 70.04 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.